The second extracellular loop of the adenosine a1 receptor mediates activity of allosteric enhancerss

Molecular Pharmacology

Volumn 85, Issue 2, 2014, Pages 301-309

  Kennedy, Dylan P ^a   McRobb, Fiona M ^b   Leonhardt, Susan A ^a   Purdy, Michael ^a   Figler, Heidi ^a   Marshall, Melissa A ^a   Chordia, Mahendra ^a   Figler, Robert ^a   Linden, Joel ^c   Abagyan, Ruben ^a,c   Yeager, Mark ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ALANINE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CHIMERA; COMPETITIVE INHIBITION; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 84891860261     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088682     Document Type: Article

References (55)

1. Abagyan R and Totrov M (1994) Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 235: 983-1002.
2. Amoah-Apraku B, Xu J, Lu JY, Pelleg A, Bruns RF, and Belardinelli L (1993) Selective potentiation by an A1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J Pharmacol Exp Ther 266: 611-617.
3. An J, Totrov M, and Abagyan R (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4:752-761.
4. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
5. Baraldi PG, Zaid AN, Lampronti I, Fruttarolo F, Pavani MG, Tabrizi MA, Shryock JC, Leung E, and Romagnoli R (2000) Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett 10:1953-1957.
6. Bhattacharya S, Youkey RL, Ghartey K, Leonard M, Linden J, and Tucker AL (2006) The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs. Biochem J 396:139-146.
7. Birdsall NJ and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543.
8. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
9. Bruns RF, Fergus JH, Coughenour LL, Courtland GG, Pugsley TA, Dodd JH, and Tinney FJ (1990) Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:950-958.
10. Burford NT, Watson J, Bertekap R, and Alt A (2011) Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81: 691-702.
11. Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, and Christopoulos A (2012) A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 287:650-659.
12. Canals M, Sexton PM, and Christopoulos A (2011) Allostery in GPCRs: 'MWC' revisited. Trends Biochem Sci 36:663-672.
13. Cardozo T, Totrov M, and Abagyan R (1995) Homology modeling by the ICM method. Proteins 23:403-414.
14. Casadó V, Allende G, Mallol J, Franco R, Lluis C, and Canela EI (1993) Thermodynamic analysis of agonist and antagonist binding to membrane-bound and solubilized A1 adenosine receptors. J Pharmacol Exp Ther 266:1463-1474.
15. Chordia MD, Zigler M, Murphree LJ, Figler H, Macdonald TL, Olsson RA, and Linden J (2005) 6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. J Med Chem 48: 5131-5139.
16. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
17. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
18. Daval J-L, von Lubitz DK, Deckert J, and Marangos PJ (1989a) Protective effects of cyclohexyladenosine following cerebral ischemia in the gerbil hippocampus. Adv Exp Med Biol 253B:447-454.
19. Daval J-L, Von Lubitz DK, Deckert J, Redmond DJ, and Marangos PJ (1989b) Protective effect of cyclohexyladenosine on adenosine A1-receptors, guanine nucleotide and forskolin binding sites following transient brain ischemia: a quantitative autoradiographic study. Brain Res 491:212-226.
20. Dhalla AK, Chisholm JW, Reaven GM, and Belardinelli L (2009) A1 adenosine receptor: Role in diabetes and obesity, in Adenosine Receptors in Health and Disease (Wilson CN and Mustafa SJ, eds) pp 271-295, Springer, Berlin Heidelberg.
21. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, and Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108:13118-13123.
22. Ellis J, Seidenberg M, and Brann MR (1993) Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. Mol Pharmacol 44:583-588.
23. Figler H, Olsson RA, and Linden J (2003) Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Mol Pharmacol 64:1557-1564.
24. Göblyös A and IJzerman AP (2011) Allosteric modulation of adenosine receptors. Biochim Biophys Acta. Biomembranes 1808:1309-1318.
25. Heitman LH, Kleinau G, Brussee J, Krause G, and Ijzerman AP (2012) Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands. Mol Cell Endocrinol 351:326-336.
26. Katritch V, Kufareva I, and Abagyan R (2011) Structure based prediction of subtypeselectivity for adenosine receptor antagonists. Neuropharmacology 60:108-115.
27. Katritch V, Rueda M, and Abagyan R (2012) Ligand-guided receptor optimization, in Homology Modeling (Orry AJW and Abagyan R, eds) pp 189-205, Humana Press, New York.
28. Katritch V, Rueda M, Lam PC-H, Yeager M, and Abagyan R (2010) GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex. Proteins 78:197-211.
29. Kollias-Baker C, Xu J, Pelleg A, and Belardinelli L (1994) Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ Res 75:972-980.
30. Kufareva I, Rueda M, Katritch V, Stevens RC, and Abagyan R; GPCR Dock 2010 participants (2011) Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 19:1108-1126.
31. Lane JR, Abdul-Ridha A, and Canals M (2013) Regulation of G protein-coupled receptors by allosteric ligands. ACS Chem Neurosci 4:527-534.
32. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AGW, and Tate CG (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-525.
33. Li X, Conklin D, Ma W, Zhu X, and Eisenach JC (2002) Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain 97:117-125.
34. Li X, Conklin D, Pan H-L, and Eisenach JC (2003) Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J Pharmacol Exp Ther 305:950-955.
35. Lin H, Sassano MF, Roth BL, and Shoichet BK (2013) A pharmacological organization of G protein-coupled receptors. Nat Methods 10:140-146.
36. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, and IJzerman AP et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236.
37. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
38. Mizumura T, Auchampach JA, Linden J, Bruns RF, and Gross GJ (1996) PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res 79:415-423.
39. Narlawar R, Lane JR, Doddareddy M, Lin J, Brussee J, and Ijzerman AP (2010) Hybrid ortho/allosteric ligands for the adenosine A1 receptor. J Med Chem 53: 3028-3037.
40. Overington JP, Al-Lazikani B, and Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996.
41. Park SW, Kim JY, Ham A, Brown KM, Kim M, D'Agati VD, and Lee HT (2012) A1 adenosine receptor allosteric enhancer PD-81723 protects against renal ischemiareperfusion injury. Am J Physiol Renal Physiol 303:F721-F732.
42. Peeters MC, Wisse LE, Dinaj A, Vroling B, Vriend G, and Ijzerman AP (2012) The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. Biochem Pharmacol 84:76-87.
43. Pietra D, Borghini A, Breschi MC, and Bianucci AM (2010) Enhancer and competitive allosteric modulation model for G-protein-coupled receptors. J Theor Biol 267: 663-675.
44. Robeva AS, Woodard R, Luthin DR, Taylor HE, and Linden J (1996) Double tagging recombinant A1- and A2A-adenosine receptors with hexahistidine and the FLAG epitope: development of an efficient generic protein purification procedure. Biochem Pharmacol 51:545-555.
45. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Iaconinoto MA, Preti D, Shryock JC, Moorman AR, and Vincenzi F et al. (2008) Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. J Med Chem 51: 5875-5879.
46. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Salvador MK, Preti D, Tabrizi MA, Moorman AR, and Vincenzi F et al. (2012) Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4-arylpiperazin-1-yl) methyl]-5-substitutedthiophenes: effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor. J Med Chem 55:7719-7735.
47. Rueda M, Totrov M, and Abagyan R (2012) ALiBERO: evolving a team of complementary pocket conformations rather than a single leader. J Chem Inf Model 52:2705-2714.
48. Stewart GD, Valant C, Dowell SJ, Mijaljica D, Devenish RJ, Scammells PJ, Sexton PM, and Christopoulos A (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J Pharmacol Exp Ther 331:277-286.
49. Tranberg CE, Zickgraf A, Giunta BN, Luetjens H, Figler H, Murphree LJ, Falke R, Fleischer H, Linden J, and Scammells PJ et al. (2002) 2-Amino-3-aroyl-4,5- alkylthiophenes: agonist allosteric enhancers at human A(1) adenosine receptors. J Med Chem 45:382-389.
50. van der Klein PAM, Kourounakis AP, and IJzerman AP (1999) Allosteric modulation of the adenosine A1 receptor: synthesis and biological evaluation of novel 2-amino- 3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42: 3629-3635.
51. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, and Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
52. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S, Ellis J, Höltje H-D, and Mohr K (2003) Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 64:21-31.
53. Wang C-IA and Lewis RJ (2013) Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 85:153-162.
54. Wojcik M, Zieleniak A, and Wozniak LA (2010) New insight into A? adenosine receptors in diabetes treatment. Curr Pharm Des 16:4237-4242.
55. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao Z-G, Cherezov V, and Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327.